TNF inhibitor use demonstrates no negative impact on survival among patients recently diagnosed with colorectal, lung or ...
TNF Pharmaceuticals (TNFA) announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was ...
In vitro tests indicate that cannabidiol can stimulate the biomineralization of teeth even under inflammatory conditions, ...
INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...
TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company that engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to ...
TNF Pharmaceuticals (TNFA) announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha inhibitor drug ...
Hosted on MSN1mon
Why anti-TNF drugs don't work for some kids with Crohn's diseaseThe resulting paper, "HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease," appears in the American Journal of Gastroenterology.
The success of agents that inhibit tumor necrosis factor (TNF), such as infliximab, adalimumab and etanercept, has led to a desire for orally available small molecules that have a better safety ...
In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of anti-TNF therapy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback